Showing results (1141-1150 of 1,205) with videos related to

Sort By:
Pageof 121
The International Journal on Drug Policy|March 20, 2026
Reinfection following direct-acting antiviral therapy for hepatitis C infection among people in prison with recent injecting drug use: the SHARP-P studyAnna Conway, Jason Grebely, Shane Tillakeratne, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 16, 2023
Patient-Reported Outcomes During and After Hepatitis C Virus Direct-Acting Antiviral Treatment Among People Who Inject DrugsQinglu Cheng, Evan B Cunningham, Sophy Shih, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 14, 2019
Patterns of Drug and Alcohol Use and Injection Equipment Sharing Among People With Recent Injecting Drug Use or Receiving Opioid Agonist Treatment During and Following Hepatitis C Virus Treatment With Direct-acting Antiviral Therapies: An International StudyAndreea A Artenie, Evan B Cunningham, Gregory J Dore, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 3, 2019
Adherence to Once-daily and Twice-daily Direct-acting Antiviral Therapy for Hepatitis C Infection Among People With Recent Injection Drug Use or Current Opioid Agonist TherapyEvan B Cunningham, Behzad Hajarizadeh, Janaki Amin, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 21, 2023
Inducible CRISPR-targeted "knockdown" of human gut <i>Bacteroides</i> in gnotobiotic mice discloses glycan utilization strategiesZachary W Beller, Darryl A Wesener, Timothy R Seebeck, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 14, 2020
Reinfection Following Successful Direct-acting Antiviral Therapy for Hepatitis C Virus Infection Among People Who Inject DrugsEvan B Cunningham, Behzad Hajarizadeh, Janaki Amin, et al.
Open Forum Infectious Diseases|April 15, 2026
A Single Dose Study of Pembrolizumab in People With HIV Infection Who are Immunologic NonrespondersJanaki Kuruppu, Julia B Purdy, Cheryl Pauls, et al.
Neurobiology of Disease|December 3, 2014
SEMA4D compromises blood-brain barrier, activates microglia, and inhibits remyelination in neurodegenerative diseaseErnest S Smith, Alan Jonason, Christine Reilly, et al.
BMC Infectious Diseases|June 15, 2017
Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE studyEvan B Cunningham, Behzad Hajarizadeh, Olav Dalgard, et al.
Scientific Reports|August 14, 2021
Patient-specific computational simulation of coronary artery bifurcation stentingShijia Zhao, Wei Wu, Saurabhi Samant, et al.
Pageof 121